Empowered Funds’s TG Therapeutics TGTX Stock Holding History

Empowered Funds’s Portfolio TGTX Stock Details TGTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$291K	Sell	5,299 -80,130	-94%	-$3.28M	﹤0.01%	1869
2026 Q1	$2.84M	Buy	85,429 +28,452	+50%	+$848K	0.02%	908
2025 Q4	$1.7M	Buy	+56,977	New	+$1.86M	0.03%	526
2025 Q1	–	Sell	-49,267	Closed	-$1.48M	–	1787
2024 Q4	$1.48M	Buy	49,267 +2,836	+6%	+$81.4K	0.02%	847
2024 Q3	$1.09M	Buy	46,431 +1,386	+3%	+$30.3K	0.02%	878
2024 Q2	$801K	Buy	+45,045	New	+$719K	0.01%	921
2021 Q2	–	Sell	-55,545	Closed	-$2.89M	–	297
2021 Q1	$2.89M	Hold	55,545	–	–	0.55%	32
2020 Q4	$2.89M	Buy	+55,545	New	+$1.88M	0.55%	32

Other funds holding TGTX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

CAM

Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return

Empowered Funds's TGTX Position: Q2 2026 in Review

Empowered Funds reduced its TG Therapeutics (TGTX) stake by 94% in Q2 2026, selling an estimated $3.28M and leaving 5,299 shares worth $291K. The position accounts for ﹤0.01% of the portfolio, ranked #1869.

Empowered Funds first reported a position in TGTX in Q4 2020 and has held it in 8 quarters since. The position peaked at $2.89M in Q1 2021. 428 funds tracked by Wall St. Rank hold TGTX as of Q2 2026.

Empowered Funds held 5,299 shares of TG Therapeutics worth $291K as of Q2 2026.
Empowered Funds sold 80,130 TG Therapeutics shares in Q2 2026, an estimated $3.28M.
TG Therapeutics made up ﹤0.01% of Empowered Funds's portfolio in Q2 2026, its #1869 holding.
Empowered Funds first reported a position in TG Therapeutics in Q4 2020 and has held it in 8 quarters since.
Empowered Funds's TG Therapeutics position peaked at $2.89M in Q1 2021.
428 funds tracked by Wall St. Rank held TG Therapeutics as of Q2 2026.

Based on Empowered Funds's 13F filing for Q2 2026, filed 17 Aug 2026.